Biacore. Concentration Analysis Handbook
|
|
- Heather Davis
- 6 years ago
- Views:
Transcription
1 Biacore Concentration Analysis Handbook
2
3 Biacore Concentration Analysis Handbook :IVWMSR%%(IGIQFIV
4 &MEGSVI 'SRGIRXVEXMSR%REP]WMW,ERHFSSO )HMXMSR(IGIQFIV:IVWMSR%% 'ST]VMKLX &MEGSVI%& %PPVMKLXWVIWIVZIH2STEVXWSJXLMWTYFPMGEXMSRQE]FIVITVSHYGIH [MXLSYX[VMXXIRTIVQMWWMSRJVSQ&MEGSVI%& &MEGSVI%&VIWIVZIWXLIVMKLXXSQEOIGLERKIWXSXLIHIWMKRERH GSRXIRXSJXLI'SRGIRXVEXMSR%REP]WMW,ERHFSSO[MXLSYXTVMSVRSXMGI &MEGSVIMWEVIKMWXIVIHXVEHIQEVOSJ&MEGSVI%& 7IRH]SYVGSQQIRXWF]IQEMPXSHIZIPSTFME$FMEGSVIGSQ &MEGSVI%& 6ETWKEXER 7)9TTWEPE7[IHIR 8IP *E\
5 Contents Contents 1. Introduction 1 4VMRGMTPIWSJ&MEGSVI &MEGSVIMRGSRGIRXVEXMSRQIEWYVIQIRX ;L]YWI&MEGSVI# %WWE]HIZIPSTQIRXSZIVZMI[ 2. Terminology 5 &MEGSVIXIVQMRSPSK] 4IVJSVQERGIGVMXIVME 7TIGMJMGMX]WIPIGXMZMX]ERHGVSWWVIEGXMZMX] %GGYVEG] 4VIGMWMSR 0MQMXSJHIXIGXMSR03( 0MQMXWSJUYERXMXEXMSR035 0MRIEVMX] 6ERKI 6SFYWXRIWW 7IRWMXMZMX] 3. Assay formats 15 (MVIGXFMRHMRKEWWE]W 7MRKPIWXITHMVIGXQIEWYVIQIRX 7ERH[MGLQIXLSHW -RHMVIGXEWWE]W -RLMFMXMSREWWE]W 7YVJEGIGSQTIXMXMSR &MRHMRKVEXIEWWE]W 'LSMGISJEWWE]XIGLRMUYI 'LSMGISJPMKERHERHSXLIVVIEKIRXW 4VEGXMGEPETTVSEGLIWXSVIEKIRXWIPIGXMSR (MVIGXFMRHMRKEWWE]W -RLMFMXMSREWWE]W 7YVJEGIGSQTIXMXMSREWWE]W 4. Surface preparation principles 27 7IRWSVWYVJEGITVSTIVXMIW 0MKERHMQQSFMPM^EXMSRQIXLSHW %QMRIGSYTPMRK 8LMSPGSYTPMRK M
6 Contents %PHIL]HIGSYTPMRK 7XVITXEZMHMRFMSXMRGETXYVI +IRIVEPGETXYVIQIXLSHW -QQSFMPM^MRKWQEPPQSPIGYPIW 'SRHMXMSRWJSVPMKERHMQQSFMPM^EXMSR &YJJIVGSRHMXMSRWERHTVIGSRGIRXVEXMSR 7XVEXIK]JSVWYVJEGITVITEVEXMSR %QSYRXSJMQQSFMPM^IHPMKERH 'LSMGISJMQQSFMPM^EXMSRQIXLSH 5. Surface preparation in practice 37 'SRHMXMSRWJSVMQQSFMPM^EXMSR -QQSFMPM^EXMSRTVSGIHYVI 4VITEVMRKWSPYXMSRW %QMRIGSYTPMRK 7YVJEGIXLMSPGSYTPMRK 0MKERHXLMSPGSYTPMRK %PHIL]HIGSYTPMRK 6IWYPXWSJMQQSFMPM^EXMSR 8IWXMRKXLIWYVJEGI 8VSYFPIWLSSXMRKWYVJEGITVITEVEXMSR 0S[MQQSFMPM^EXMSRPIZIPW 0S[EREP]XIVIWTSRWIW 6. Regeneration 49 6IKIRIVEXMSRWGSYXMRKWXVEXIK] 'LSMGISJVIKIRIVEXMSRWSPYXMSR 8IWXMRKVIKIRIVEXMSRGSRHMXMSRW -RXIVTVIXMRKVIKIRIVEXMSRWGSYXMRK 6ITSVXTSMRXTPEGMRK 8VIRHTPSXW 7. Developing and running concentration assays 55 %WWE]VIUYMVIQIRXWTIGMJMGEXMSR +IRIVEPTVEGXMGEPGSRWMHIVEXMSRW 4VITEVMRKWEQTPIW 6ITSVXTSMRXTPEGMRK %HNYWXMRKXLISTIVEXMRKVERKI (MVIGXFMRHMRKEWWE]W -RLMFMXMSREWWE]W 9R[ERXIHFMRHMRKSJEREP]XISVHIXIGXMRKQSPIGYPI XSXLIWIRWSVWYVJEGI 9R[ERXIHFMRHMRKMRHMVIGXFMRHMRKEWWE]W 9R[ERXIHFMRHMRKMRMRLMFMXMSRERHWYVJEGIGSQTIXMXMSR EWWE]W MM
7 Contents 8IWXMRKJSVYR[ERXIHFMRHMRK (IEPMRK[MXLYR[ERXIHFMRHMRK 7TIGMJMGMX]ERHGVSWWVIEGXMZMX] 1IEWYVMRKWTIGMJMGMX] 3TXMQM^MRKWTIGMJMGMX] 1EXVM\MRXIVJIVIRGI 2SRWTIGMJMGFMRHMRKXSXLIWIRWSVWYVJEGI 3XLIVQEXVM\MRXIVJIVIRGIIJJIGXW %WWE]WXEFMPMX] 8IWXMRKEWWE]WXEFMPX] (IEPMRK[MXLEWWE]WXEFMPMX]MWWYIW 6YRRMRKVSYXMRIEWWE]W 8. Measuring concentration in GxP environments 73 7IXXMRKYT+\4EWWE]W 7]WXIQTIVJSVQERGI %WWE]WIXXMRKW %WWE]TVSGIHYVIHSGYQIRXEXMSR (EXEWXSVEKI :EPMHEXMRK+\4EWWE]W 7TIGMJMGMX] %GGYVEG] 4VIGMWMSR 0MRIEVMX] 6ERKI 6SFYWXRIWW 6YRRMRK+\4EWWE]W (SGYQIRXXLIVYRWIXXMRKW (EXEWXSVEKI %YHMXXVEMPW A. The SPR detection principle 79 % 7YVJEGITPEWQSRVIWSRERGI % ;LEX746QIEWYVIW % &MEGSVIGSRJMKYVEXMSR B. Using binding rates to measure concentration 83 & *EGXSVWHIXIVQMRMRKFMRHMRKVEXIW & &MSGLIQMGEPMRXIVEGXMSRVEXIW & 1EWWXVERWTSVXTVSGIWWIW & ;LEXPMQMXWXLISFWIVZIHFMRHMRK# & %JJMRMX]MRHITIRHIRXEWWE]W & %HZERXEKIWSJEJJMRMX]MRHITIRHIRXEWWE]W & %JJMRMX]MRHITIRHIRXEWWE]WMRTVEGXMGI & 'EPMFVEXMSRMRHITIRHIRXEWWE]W MMM
8 Contents MZ
9 Introduction 1. Introduction 1.1 Principles of Biacore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iacore in concentration measurement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
10 Introduction 8LMWLERHFSSOTVSZMHIWKYMHIPMRIWJSVLS[XSHIZIPSTERHYWI GSRGIRXVEXMSREWWE]W[MXL&MEGSVIW]WXIQW8LIMRJSVQEXMSRMWKMZIREW JEVEWTSWWMFPIMRKIRIVEPXIVQW[MXLSYXHMVIGXVIJIVIRGIXSWTIGMJMG &MEGSVIW]WXIQW8LITVMRGMTPIWSJEWWE]HIZIPSTQIRXERH GSRGIRXVEXMSRHIXIVQMREXMSRGEREPWSFIETTPMIH[MXLETTVSTVMEXI EHNYWXQIRXWXSEWWE]WFEWIHSRSXLIVXIGLRSPSKMIW 1.3 Why use Biacore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
11 Introduction 1.4 Assay development overview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
12 Introduction
13 Terminology 2. Terminology 8LMWGLETXIVTVIWIRXWXLIXIVQMRSPSK]XLEXMWYWIHMRXLIGSRXI\XSJ GSRGIRXVEXMSRQIEWYVIQIRXW[MXL&MEGSVI8LIJMVWXWIGXMSRTVIWIRXW XIVQWWTIGMJMGXS&MEGSVIETTPMGEXMSRWERHXLIWIGSRHWIGXMSRHIJMRIW XLIXIVQWYWIHXSHIWGVMFIEWWE]TIVJSVQERGIMRXLIGSRXI\XSJ ZEPMHEXIHEREP]XMGEPTVSGIHYVIW 2.1 Biacore terminology &MEGSVIW]WXIQWQSRMXSVXLIMRXIVEGXMSRFIX[IIRX[SQSPIGYPIWSJ [LMGLSRIMWEXXEGLIHXSXLIWIRWSVWYVJEGIERHXLISXLIVMWJVIIMR WSPYXMSR8LIJSPPS[MRKXIVQWEVIYWIHMRXLIGSRXI\XSJGSRGIRXVEXMSR QIEWYVIQIRX[MXL&MEGSVI 8LITEVXRIVEXXEGLIHXSXLIWYVJEGIMWGEPPIHXLIPMKERH%XXEGLQIRX QE]FIGSZEPIRXSVXLVSYKLLMKLEJJMRMX]FMRHMRKXSERSXLIV QSPIGYPI[LMGLMWMRXYVRGSZEPIRXP]EXXEGLIHXSXLIWYVJEGIWII 'LETXIV-RXLIPEXXIVGEWIXLIQSPIGYPIEXXEGLIHXSXLIWYVJEGIMW VIJIVVIHXSEWXLIGETXYVMRKQSPIGYPI8LIXIVQlPMKERHzMW ETTPMIHLIVIMREREPSK][MXLXIVQMRSPSK]YWIHMREJJMRMX] GLVSQEXSKVETL]GSRXI\XWERHHSIWRSXMQTP]XLEXXLIWYVJEGI EXXEGLIHQSPIGYPIMWEPMKERHJSVEGIPPYPEVVIGITXSV 8LIEREP]XIMWXLIQSPIGYPIJSV[LMGLXLIGSRGIRXVEXMSRMWXSFI QIEWYVIH-RHMVIGXFMRHMRKEWWE]WXLIEREP]XIFMRHWHMVIGXP]XSXLI PMKERH-RMRLMFMXMSREWWE]WXLIGSRGIRXVEXMSRSJEREP]XIMW QIEWYVIHMRHMVIGXP]XLVSYKLFMRHMRKSJEREHHMXMSREPQSPIGYPI analyte analyte ligand ligand capturing molecule Figure 2-1. Ligand, analyte and capturing molecule in relation to the sensor surface. 8LIHIXIGXMRKQSPIGYPIMWXLIQSPIGYPIVIWTSRWMFPIJSVHIXIGXMRKXLI EREP]XI-RHMVIGXFMRHMRKEWWE]WXLIHIXIGXMRKQSPIGYPIMWXLIWEQI EWXLIPMKERH-RMRLMFMXMSREWWE]WXLIHIXIGXMRKQSPIGYPIMWXLI QSPIGYPIXLEXFMRHWXSXLIPMKERHERHKIRIVEXIWEVIWTSRWI[LMGLMW FPSGOIHF]XLITVIWIRGISJEREP]XI
14 Terminology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bsolute response (RU) Report points Relative response (RU) Buffer Sample Buffer Regeneration Buffer Time Figure 2-2. Schematic illustration of a sensorgram. The bars below the sensorgram curve indicate the solutions that pass over the sensor surface. 8LIWEQTPIQEXVM\MWXLIWSPYXMSRIRZMVSRQIRXMR[LMGLEREP]XIMW TVIWIRXMRWEQTPIW8LMWQE]FIEWMQTPI[IPPHIJMRIHWSPYXMSRWYGL EWEFYJJIVSVEGSQTPI\QM\XYVIWYGLEWEFSH]JPYMHGIPPI\XVEGX SVTVSHYGXJSVQYPEXMSR8LIXIVQQEXVM\MWEPWSYWIHXSVIJIVXS XLIGEVFS\]QIXL]PHI\XVERSRXLIWYVJEGISJXLIWIRWSVGLMTMR &MEGSVIEWHIWGVMFIHMR7IGXMSR8LMWYWEKIMWMRRS[E] GSRRIGXIHXSXLIXIVQWEQTPIQEXVM\
15 Terminology 2.2 Performance criteria,s[izivgsrgirxvexmsrmwqiewyvihxlivimwewixsjwxerhevhm^ih GVMXIVMEXLEXQIEWYVIXLITIVJSVQERGISJXLIEWWE][MXLMRERHFIX[IIR EWWE]SGGEWMSRW(SGYQIRXIHTIVJSVQERGIMWHIWMVEFPIMREPP GSRGIRXVEXMSRQIEWYVIQIRXWERHMWEVIUYMVIQIRXJSVZEPMHEXIHEWWE]W YWIHMRUYEPMX]GSRXVSPERHSXLIVGSRXI\XW8LIWXERHEVHTIVJSVQERGI GVMXIVMEHIJMRIHMRXLIJSPPS[MRKWIGXMSRWEVIFEWIHSRXLI-', VIGSQQIRHEXMSRW 'SRWMHIVEXMSRWSJLS[XSQIEWYVITIVJSVQERGI GVMXIVMEJSVEKMZIREWWE]EVIGSRWMHIVIHMR'LETXIV Specificity, selectivity and cross-reactivity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
16 Terminology 100 Response/MW Compound A 50 Compound B Concentration Figure 2-3. Cross-reactivity in a direct assay is determined from calibration curves of molecular weight-corrected response against concentration. In this illustration, compound B shows 1% cross-reactivity with compound A Accuracy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recision 8LITVIGMWMSRSJEREWWE]HIWGVMFIWXLIEKVIIQIRXHIKVIISJWGEXXIV FIX[IIRVIWYPXSFXEMRIHJVSQQYPXMTPIQIEWYVIQIRXWSRXLIWEQI LSQSKIRISYWWEQTPI4VIGMWMSRQE]FIHIXIVQMRIHEXXLVIIPIZIPW 6ITIEXEFMPMX]MWXLITVIGMWMSRSJXLIEWWE]YRHIVXLIWEQISTIVEXMRK GSRHMXMSRW[MXLXLIWEQIWEQTPISZIVEWLSVXTIVMSHSJXMQI
17 Terminology X]TMGEPP]VITPMGEXIQIEWYVIQIRXW[MXLMRXLIWEQII\TIVMQIRXEPWS VIJIVVIHXSEWMRXVEEWWE]TVIGMWMSR -RXIVQIHMEXITVIGMWMSRMWXLITVIGMWMSR[MXLMRXLIWEQIPEFSVEXSV] SZIVHMJJIVIRXSGGEWMSRWHMJJIVIRXSTIVEXSVWHMJJIVIRXMRHMZMHYEP EWWE]MRWXVYQIRXWIXG6YKKIHRIWWMWEREPXIVREXMZIXIVQJSV MRXIVQIHMEXITVIGMWMSR 6ITVSHYGMFMPMX]MWXLITVIGMWMSRFIX[IIRHMJJIVIRXPEFSVEXSVMIW YWYEPP]ETTPMIHXSGSPPEFSVEXMZIWXYHMIWMRXLIWXERHEVHM^EXMSRSJ QIXLSHSPSK]-RXIVQIHMEXITVIGMWMSRERHVITVSHYGMFMPMX]EVIX[S HMJJIVIRXEWTIGXWSJMRXIVEWWE]TVIGMWMSR 8LITVIGMWMSRSJEREWWE]MWYWYEPP]I\TVIWWIHMRXIVQWSJXLIZEVMERGI WXERHEVHHIZMEXMSR7(SVGSIJJMGMIRXSJZEVMEXMSR':[MXLMRXLI WIVMIWSJQIEWYVIQIRXW*SVEWIXSJVITPMGEXIQIEWYVIQIRXWXLI WXERHEVHHIZMEXMSRMWKMZIRF] 7( = ( R ) (] ]) M [LIVIR!RYQFIVSJQIEWYVIQIRXW ERH]!VIWTSRWIJSVEKMZIRQIEWYVIQIRX 8LIGSIJJMGMIRXSJZEVMEXMSRMWKMZIRF] 7( ': = QIER 7XEXMWXMGEPTEVEQIXIVWJSVZEVMEXMSRMRQIEWYVIHVIWYPXWQE]FIVIPEXIH XSIMXLIVHSWISVVIWTSRWIZEPYIWXLMWMWTIVLETWQSWXGSQQSRMR GMXEXMSRWSJ':ZEPYIW[LIVIXLIHMWXMRGXMSRMWQEHIFIX[IIR': HSWI ERH': VIWTSRWI 8LI': VIWTSRWI ZEPYIVIJPIGXWXLIGSRWMWXIRG]SJ VIWTSRWIZEPYIWJSVEKMZIRGSRGIRXVEXMSR[LMPI': HSWI VIJPIGXWXLI GSRJMHIRGI[MXL[LMGLEKMZIRVIWTSRWIZEPYIGERFIVIPEXIHXSEREP]XI GSRGIRXVEXMSR-RKIRIVEP': HSWI ZEPYIWEVILMKLEXXLIXSTERH FSXXSQSJXLIQIEWYVIQIRXVERKIEXXLIFSXXSQFIGEYWIPS[ VIWTSRWIWEVIHMJJMGYPXXSHIXIVQMRIEGGYVEXIP]EXXLIXSTFIGEYWIXLI WXERHEVHGYVZIJPEXXIRWSYXEXLMKLGSRGIRXVEXMSRWERHEVIPS[IWXMR XLIQMHHPISJXLIVERKI': VIWTSRWI ZEPYIWSRXLISXLIVLERHEVI JVIUYIRXP]PS[IZIREXXLIXSTSJXLIH]REQMGVERKI': HSWI MWMR KIRIVEPEFIXXIVGVMXIVMSRSJEWWE]TIVJSVQERGIXLER': VIWTSRWI
18 Terminology Response CV response CV dose Concentration Figure 2-4. CV response is an indication of the variability in the response for a given analyte concentration. CV dose is an indication of the variability in calculated concentration derived from a given set of measurements. %GGYVEG]ERHTVIGMWMSREVIJVIUYIRXP]GSRJYWIHMRGSQQSRTEVPERGI EPXLSYKLXLI]EVIGPIEVP]HMWXMRKYMWLIHMRXLIMVJSVQEPHIJMRMXMSRW%R EWWE]XLEXMWTVIGMWIFYXRSXEGGYVEXI[MPPEP[E]WKMZIXLIWEQI [VSRKERW[IV[LMPISRIXLEXMWEGGYVEXIFYXRSXTVIGMWI[MPPKMZIER ETTVS\MQEXIFYXGSVVIGXERW[IV Limit of detection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imits of quantitation (LOQ) (IXIVQMREXMSRSJXLI035SJEREWWE]VIUYMVIWXLEXXLITVIGMWMSRERH EGGYVEG]SJXLIEWWE]EVIQIEWYVIHSZIVEVERKISJEREP]XI GSRGIRXVEXMSRWMRSVHIVXSHIXIVQMRIXLIGSRGIRXVEXMSRWEFSZIERH FIPS[[LMGLXLITIVJSVQERGIMWEGGITXEFPI8LIWIGSRGIRXVEXMSRWEVI
19 Terminology XLIRXLI035WHMJJIVIRXZEPYIWQE]FIETTPMGEFPIEGGSVHMRKXS [LIXLIVTVIGMWMSRMWHIXIVQMRIHEWMRXIVQIHMEXITVIGMWMSRSV VITVSHYGMFMPMX]8LI035WLSYPHRSXFIFEWIHSRVITIEXEFMPMX]SV MRXVEEWWE]TVIGMWMSRWMRGIXLIZEPYILEWPMXXPIQIERMRKMRVIJIVIRGIXS EWMRKPIEWWE]SGGEWMSR 8LIPS[IVPMQMXSJUYERXMXEXMSR0035MWXLIPS[IWXEREP]XI GSRGIRXVEXMSRXLEXGERFIQIEWYVIH[MXLWYMXEFPITVIGMWMSRERH EGGYVEG]8LIPIZIPGSVVIWTSRHMRKXSlWYMXEFPIz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esponse 3xSD acceptable precision and accuracy Limit of detection Limits of quantitation Concentration Figure 2-5. Limits of detection and quantitation.
20 Terminology Linearity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ange 8LIVERKISJEREWWE]MWXLIMRXIVZEPFIX[IIRERHMRGPYHMRKXLIYTTIV ERHPS[IVPMQMXWSJUYERXMXEXMSRMIXLIVERKI[MXLMR[LMGLXLI TVIGMWMSREGGYVEG]ERHPMRIEVMX]EVIEGGITXEFPI %TEVEQIXIVSJXIRUYSXIHMRVIPEXMSRXSXLIVERKIMWXLIEREP]XI GSRGIRXVEXMSRXLEXKMZIWSJXLIQE\MQYQVIWTSRWI& JSVE HMVIGXFMRHMRKEWWE]-' JSVERMRLMFMXMSREWWE]2SXIXLEXXLMWMWRSX RIGIWWEVMP]XLIQMHTSMRXSJXLIGSRGIRXVEXMSRVERKI Response/MW 100% Response 100% 50% 50% 0 B 50 Concentration 0 IC 50 Concentration Figure 2-6. B 50 (direct assays, left panel) and IC 50 (inhibition assays, right panel) are the analyte concentration that gives 50% of the maximum response.
21 Terminology Robustness 8LIVSFYWXRIWWSJEREWWE]MWEQIEWYVISJMXWGETEGMX]XSVIQEMR YREJJIGXIHF]ZEVMEXMSRWMRQIXLSHTEVEQIXIVW6SFYWXRIWWMWVIPEXIH XSMRXIVQIHMEXITVIGMWMSRSVVYKKIHRIWW;LMPIMRXIVQIHMEXITVIGMWMSR VIJIVWXSXLIIJJIGXSJYRMRXIRXMSREPZEVMEXMSRWFIX[IIREWWE]SGGEWMSRW STIVEXSVIXGWII7IGXMSRVSFYWXRIWWMWHIXIVQMRIHF]QIERWSJ HIPMFIVEXIZEVMEXMSRWMRGLSWIREWWE]TEVEQIXIVW%REWWE]XLEXMW VSFYWX[MXLVIWTIGXXSEPPIWWIRXMEPTEVEQIXIVW[MPPEPWSLEZIELMKL PIZIPSJMRXIVQIHMEXITVIGMWMSR Sensitivity 8LIWIRWMXMZMX]SJEREWWE]MWRSXMRGPYHIHEQSRKXLIVIGSQQIRHIH TIVJSVQERGIGVMXIVMEJSVZEPMHEXMSRFYXMW[SVXL]SJEHIJMRMXMSRLIVI FIGEYWIXLIXIVQMWSJXIRYWIHMRWIZIVEPHMJJIVIRXERHXSWSQII\XIRX GSRJPMGXMRKWIRWIW*SVQEPP]WIRWMXMZMX]MWHIJMRIHEWXLIEWWE]VIWTSRWI TIVYRMXEREP]XIGSRGIRXVEXMSRIK69TIV KQPSV69 18LMWMW XLIWPSTISJXLIWXERHEVHGYVZIJSVXLIEWWE]*SVEWWE]W[LIVIXLI WXERHEVHGYVZIMWRSXPMRIEVXLIWIRWMXMZMX]ZEVMIW[MXLXLIEREP]XI GSRGIRXVEXMSR8LIXIVQlWIRWMXMZMX]zMWLS[IZIVWSQIXMQIWYWIHEWE W]RSR]QJSV03(SV035XLIPS[IWXGSRGIRXVEXMSRXLEXGERFI HIXIGXIHSVQIEWYVIHSVVIWSPYXMSRXLIWQEPPIWXHMJJIVIRGIMR GSRGIRXVEXMSRXLEXGERFIHIXIVQMRIH[MXLGSRJMHIRGI&MEGSVI VIGSQQIRHWYWEKISJXLIXIVQMRXLIJMVWXWIRWIEWWE]VIWTSRWITIV YRMXEREP]XIGSRGIRXVEXMSR Response Sensitivity = slope Concentration Figure 2-7. Sensitivity is the response per unit analyte concentration, which is the slope of the calibration curve. The sensitivity varies over the range of the assay if the calibration curve is not linear.
22 Terminology
23 Assay formats 3. Assay formats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
24 Assay formats analyte analyte enhancement molecule ligand ligand Direct binding assay 1 2 Direct binding assay with enhancement detecting molecule competing analyte analyte analyte ligand ligand Inhibition assay (solution competition) Surface competition assay Figure 3-1. Schematic illustration of four different approaches to concentration measurement with Biacore. 3.1 Direct binding assays &MRHMRKPIZIPEWWE]WVITVIWIRXXLIQSWXHMVIGXETTVSEGLXSQIEWYVMRK GSRGIRXVEXMSR[MXL&MEGSVI8LIHIXIGXMRKQSPIGYPIMWEXXEGLIHXSXLI WIRWSVGLMTWYVJEGIWEQTPIMWMRNIGXIHERHXLIVIWTSRWISFXEMRIHEJXIV EJM\IHGSRXEGXXMQIMWQIEWYVIH8LIVIWTSRWIMWVIPEXIHXSEREP]XI GSRGIRXVEXMSR[MXLXLILIPTSJEWXERHEVHGYVZITVITEVIHF]EREP]^MRK ORS[RGSRGIRXVEXMSRWSJEREP]XIYRHIVXLIWEQIGSRHMXMSRW Single step direct measurement (MVIGXQIEWYVIQIRXMWWYMXEFPIJSVQEGVSQSPIGYPEVEREP]XIW QSPIGYPEV[IMKLX"HEPXSRW[LMGLKMZIERIEWMP]QIEWYVIH VIWTSRWIIZIREXPS[QSPEVGSRGIRXVEXMSRW (YVMRKMRNIGXMSRSJWEQTPIXLIVIWTSRWIMRGVIEWIWEWEJYRGXMSRSJ XMQIEWEREP]XIFMRHWXSXLIWYVJEGIVIEGLMRKEWXIEH]WXEXIZEPYIMJXLI GSRXEGXXMQIMWWYJJMGMIRXP]PSRK(ITIRHMRKSRXLIXMQIEX[LMGLXLI
25 Assay formats VIWTSRWIMWQIEWYVIHXLIWIRWMXMZMX]ERHSTIVEXMRKVERKISJXLIEWWE] [MPPFIHMJJIVIRX*MKYVI Response 2 1 Response 1 2 Time Concentration Figure 3-2. A single step direct assay gives an increasing response with increasing concentration. The range and sensitivity are determined in part by the time at which the response is measured: an interaction that is allowed to approach equilibrium will give a higher sensitivity at low analyte concentrations. The inset shows the sensorgrams from which the calibration curves are derived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andwich methods 7ERH[MGLQIXLSHWEVIERI\XIRWMSRSJXLIWMRKPIWXITHMVIGXETTVSEGL EJXIVEREP]XILEWFSYRHXSXLIWYVJEGIEXXEGLIHPMKERHEWIGSRHEV] MRXIVEGXERXXLIIRLERGIQIRXQSPIGYPIMWMRNIGXIHXSFMRHXSXLI EREP]XIERHIRLERGIXLIEREP]XIVIWTSRWI-JXLIWIGSRHEV]EREP]XIMWE
26 Assay formats PEVKIVQSPIGYPIXLERXLIEREP]XIXLIWIGSRHEV]VIWTSRWI[MPPFI TVSTSVXMSREPP]LMKLIVXLERXLITVMQEV]VIWTSRWISFXEMRIHJVSQXLI EREP]XIMXWIPJTVSZMHMRKEREQTPMJMGEXMSRSJXLIWMKREP*MKYVI Response 2 1 Response 1 2 Time Concentration Figure 3-3. Sensorgrams (inset) and calibration curves for a direct binding assay with enhancement. : primary response (analyte), : secondary response (enhancement reagent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
27 Assay formats 3.2 Indirect assays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nhibition assays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esponse Response Concentration log[concentration] Figure 3-4. Inhibition and surface competition assays give a calibration curve where the response is inversely related to the analyte concentration. Calibration curves are often shown on a log[concentration] scale (right panel) to expand the low concentration region. 'PIEVP]MXMWIWWIRXMEPXLEXHIXIGXMRKQSPIGYPIWGEVV]MRKFSYRHEREP]XI MRWSPYXMSRWLSYPHRSXFIEFPIXSFMRHXSXLIWYVJEGIEXXEGLIHPMKERH -HIEPP]XLI,1;HIXIGXMRKQSPIGYPIWLSYPHFIQSRSZEPIRXJSVXLMW
28 Assay formats VIEWSR,S[IZIVQSRSGPSREPERXMFSHMIWEVIGSQQSRP]YWIHEW HIXIGXMRKQSPIGYPIWMRWTMXISJXLIMVFMZEPIRXFMRHMRKTVSTIVXMIW)ZIR XLSYKLFSXLERXMKIRFMRHMRKWMXIWQYWXFISGGYTMIHXSIJJIGXMZIP] MRLMFMXXLIFMRHMRKSJERXMFSH]XSXLIWYVJEGIXLIMRLMFMXMSREWWE] TVMRGMTPIWXMPP[SVOWVIPMEFP]ERHERXMFSHMIWEVISJXIRXLIQSWXVIEHMP] EZEMPEFPIWSYVGISJHIXIGXMRKQSPIGYPIW 8LIEJJMRMX]SJXLIHIXIGXMRKQSPIGYPIJSVXLIEREP]XIMRWSPYXMSR XSKIXLIV[MXLXLIGSRGIRXVEXMSRSJHIXIGXMRKQSPIGYPIHIXIVQMRIWXLI YWIJYPVERKISJERMRLMFMXMSREWWE],MKLIVEJJMRMXMIWEPPS[ QIEWYVIQIRXEXPS[IVEREP]XIGSRGIRXVEXMSRWFYXEPWSVIWYPXMRE REVVS[IVSTIVEXMRKVERKI*MKYVI-RJSVQEPXIVQWXLI-' SJER MRLMFMXMSREWWE]MWKMZIRF] -' = /( + ' [LIVI/ ( MWXLIIUYMPMFVMYQHMWWSGMEXMSRGSRWXERXJSVXLIMRXIVEGXMSR [MXLEREP]XIERH'MWXLIXSXEPGSRGIRXVEXMSRSJHIXIGXMRKQSPIGYPI-J XLIGSRGIRXVEXMSRMWQYGLWQEPPIVXLERXLIHMWWSGMEXMSRGSRWXERXXLI VERKI[MPPFIHIXIVQMRIHTVMQEVMP]F]XLIEJJMRMX]GSRZIVWIP]MJXLI GSRGIRXVEXMSRMWQYGLLMKLIVXLERXLIHMWWSGMEXMSRGSRWXERXXLIVERKI [MPPFIHIXIVQMRIHTVMQEVMP]F]XLIGSRGIRXVEXMSR Response Increasing affinity Increasing concentration of detecting molecule log[concentration] Figure 3-5. Increasing the affinity of the detecting molecule moves the operating range to lower analyte concentration and also narrows the range. -RLMFMXMSREWWE]WEVIQSWXGSQQSRP]YWIHJSV01;EREP]XIW8LI] QE]LS[IZIVEPWSFIYWIHEWEREPXIVREXMZIXSHMVIGXFMRHMRKPIZIP EWWE]WJSVQEGVSQSPIGYPEVEREP]XIWMRWMXYEXMSRW[LIVI MQQSFMPM^EXMSRSVVIKIRIVEXMSRSJXLIHIXIGXMRKQSPIGYPISRXLIWIRWSV WYVJEGIMWRSXWEXMWJEGXSV]
29 Assay formats Surface competition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
30 Assay formats 3.3 Binding rate assays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esponse Initial binding rate Binding level Figure 3-6. Binding rate and binding level measurements. Time &MRHMRKVEXIQIEWYVIQIRXWERHXLIGSRHMXMSRWVIUYMVIHJSVXLIMVYWI EVIGSRWMHIVIHMR%TTIRHM\&
31 Assay formats 3.4 Choice of assay technique %WHMWGYWWIHEFSZI&MEGSVIW]WXIQWSJJIVERYQFIVSJHMJJIVIRX ETTVSEGLIWXSQIEWYVMRKGSRGIRXVEXMSR8LIGLSMGISJETTVSEGLMW HMGXEXIHPEVKIP]F]XLIGLEVEGXIVMWXMGWSJXLIEREP]XIFIMRKEWWE]IHERH XSWSQII\XIRXF]XLITYVTSWISJXLIEWWE]ERHXLIX]TISJWEQTPI QEXVM\XLEX[MPPFIYWIH8LIXEFPIFIPS[TVSZMHIWWSQIKIRIVEP KYMHIPMRIW 1EGVSQSPIGYPIW X]TMGEPP]1; "HEPXSRW (MVIGXEWWE][MXLXLIHIXIGXMRKQSPIGYPI EXXEGLIHXSXLIWIRWSVWYVJEGI 7ERH[MGLEWWE]GERLIPTXS reqtpmj]xliviwtsrwijsvqspigypiwexxli PS[IRHSJXLIWM^IVERKI rgsrjmvqxlimhirxmx]sjxlierep]ximr GSQTPI\QM\XYVIW rgsrjmvqxlimrxikvmx]sjqypxmjyrgxmsrep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
32 Assay formats 3.5 Choice of ligand and other reagents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ractical approaches to reagent selection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irect binding assays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
33 Assay formats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nhibition assays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
34 Assay formats Surface competition assays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
35 Sensor Chip CM5 Certified Grade Surface preparation principles 4. Surface preparation principles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ensor surface properties 8LIWIRWSVGLMTMWEKPEWWWPMHIGSEXIH[MXLEXLMRPE]IVSJKSPHXS [LMGLEQEXVM\SJGEVFS\]QIXL]PEXIHHI\XVERMWGSZEPIRXP]EXXEGLIH *MKYVI8LIKSPHMWVIUYMVIHJSVKIRIVEXMSRSJXLI746VIWTSRWI %TTIRHM\%0MKERHWGERFIEXXEGLIHXSXLIHI\XVERQEXVM\YWMRKE ZEVMIX]SJGLIQMGEPQIXLSHW Dextran matrix Gold layer Glass Figure 4-1. Schematic illustration of the structure of the sensor chip surface.
36 Surface preparation principles 8LIKSPHPE]IVERHHI\XVERQEXVM\SRXLIWIRWSVWYVJEGIEVIWXEFPI YRHIVE[MHIVERKISJGSRHMXMSRWMRGPYHMRKI\XVIQIWSJT,ERH QSHIVEXIGSRGIRXVEXMSRWSJQER]SVKERMGWSPZIRXW3RGIXLIPMKERH LEWFIIRMQQSFMPM^IHXLIWXEFMPMX]SJXLIWIRWSVWYVJEGIMWHIXIVQMRIH TVMQEVMP]F]XLIWXEFMPMX]SJXLIEXXEGLIHPMKERH 4.2 Ligand immobilization methods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mine coupling %QMRIGSYTPMRKGLIQMWXV]MWXLIQSWX[MHIP]ETTPMGEFPIETTVSEGLJSV EXXEGLMRKFMSQSPIGYPIWGSZEPIRXP]XSXLIWIRWSVWYVJEGI;MXLXLMW QIXLSHXLIHI\XVERQEXVM\SRXLIWIRWSVGLMTWYVJEGIMWJMVWXEGXMZEXIH [MXLEQM\XYVISJIXL]PHMQIXL]PEQMRSTVST]PGEVFSHMMQMHI )('ERH2L]HVS\]WYGGMRMQMHI2,7XSKMZIVIEGXMZIWYGGMRMQMHI IWXIVW0MKERHMWXLIRTEWWIHSZIVXLIWYVJEGIERHXLIIWXIVWVIEGX WTSRXERISYWP][MXLYRGLEVKIHEQMRSKVSYTWSVSXLIVRYGPISTLMPMG KVSYTWXSPMROXLIPMKERHGSZEPIRXP]XSXLIHI\XVERWII*MKYVI
37 Surface preparation principles Figure 4-2. Amine coupling of ligands to the sensor surface. 1SWXTVSXIMRWGSRXEMRWIZIVEPEQMRIKVSYTWWSXLEXIJJMGMIRX EXXEGLQIRXGERFIEGLMIZIH[MXLSYXWIVMSYWP]EJJIGXMRKXLIFMSPSKMGEP EGXMZMX]SJXLIPMKERH-RWSQIMRWXERGIWLS[IZIVEQMRIGSYTPMRKQE] MRZSPZIKVSYTWEXSVRIEVXLIEGXMZIWMXISVFMRHMRKWMXISJXLIPMKERH [MXLXLIVIWYPXXLEXEXXEGLQIRXMWEGGSQTERMIHF]PSWWSJEGXMZMX]-R WYGLGEWIWXLIPMKERHGERFIEXXEGLIHYWMRKEPXIVREXMZIGSYTPMRK GLIQMWXV]SVEGETXYVMRKETTVSEGL Thiol coupling 8LMSPGSYTPMRKYXMPM^IWI\GLERKIVIEGXMSRWFIX[IIRXLMSPERHEGXMZI HMWYPJMHIKVSYTW8LIEGXMZIHMWYPJMHIQSMIX]QE]FIMRXVSHYGIHIMXLIV SRXLIHI\XVERQEXVM\XSI\GLERKI[MXLEXLMSPKVSYTSRXLIPMKERH VIJIVVIHXSEWXLIPMKERHXLMSPETTVSEGLSVSRXLIPMKERHQSPIGYPIXS I\GLERKI[MXLEXLMSPKVSYTMRXVSHYGIHSRXLIHI\XVERQEXVM\ VIJIVVIHXSEWXLIWYVJEGIXLMSPETTVSEGL%VIGSQQIRHIHVIEKIRXJSV MRXVSHYGMRKEGXMZIHMWYPJMHIKVSYTWMWT]VMHMR]PHMXLMSIXLERIEQMRI 4()%*MKYVI8LIEQMRIKVSYTMR4()%GERFIYWIHXSEXXEGL XLIQSPIGYPIXSEGXMZEXIHGEVFS\]PKVSYTWSRIMXLIVXLIWYVJEGISVXLI PMKERH*MKYVIMPPYWXVEXIWXLIX[SXLMSPGSYTPMRKETTVSEGLIW N SSCH 2 CH 2 NH 2 HCl Figure 4-3. PDEA Thiol coupling reagent, 2-(2-pyridinyldithio)ethaneamine hydrochloride.
38 Surface preparation principles /LJDQGWKLRO 6XUIDFHWKLRO Figure 4-4. Ligand thiol and surface thiol coupling of ligands to the sensor surface. 8LMSPGSYTPMRKGERFIEZEPYEFPIETTVSEGLMJXLIPMKERHMWMREGXMZEXIH F]EQMRIGSYTPMRKEWEVIWYPXSJXLITVIWIRGISJEREGXMZIEQMRIKVSYT MRXLIEREP]XIFMRHMRKWMXI8LIXLMSPETTVSEGLGEREPWSLIPTXS MQQSFMPM^IPMKERHWMREHIJMRIHSVMIRXEXMSRWMRGIXLIRYQFIVSJ TSXIRXMEPEXXEGLQIRXWMXIWMWSJXIRPIWWXLER[MXLEQMRIGSYTPMRKERH MRQER]GEWIWMWVIHYGIHXSSRIWMRKPIWMXI7YVJEGIXLMSPGSYTPMRKMW EPWSZEPYEFPIJSVEGMHMGTVSXIMRWWMRGIXLIWYFWXMXYXMSR[MXL4()% VEMWIWXLIMWSIPIGXVMGTSMRXSJXLITVSXIMRMQTVSZMRKXLIIPIGXVSWXEXMG TVIGSRGIRXVEXMSRTVSTIVXMIWWII7IGXMSR Aldehyde coupling 0MKERHWGSRXEMRMRKEPHIL]HIKVSYTWIMXLIVREXMZISVMRXVSHYGIHF] S\MHEXMSRSJGMWHMSPWGERFIMQQSFMPM^IHEJXIVEGXMZEXMRKXLIWYVJEGI [MXLL]HVE^MRISVGEVFSL]HVE^MHI8LIGLIQMWXV]SJEPHIL]HIGSYTPMRK MWWYQQEVM^IHMR*MKYVI Figure 4-5. Aldehyde coupling of ligands to the sensor surface.
39 Surface preparation principles %PHIL]HIGSYTPMRKTVSZMHIWEREPXIVREXMZIETTVSEGLJSVMQQSFMPM^MRK KP]GSTVSXIMRWERHSXLIVKP]GSGSRNYKEXIW8LIQIXLSHMWTEVXMGYPEVP] WYMXEFPIJSVPMKERHWGSRXEMRMRKWMEPMGEGMHWMRGIXLIWIVIWMHYIWEVIZIV] IEWMP]S\MHM^IHXSEPHIL]HIW Streptavidin-biotin capture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eneral capture methods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
40 Surface preparation principles 8LIFEWMGVIUYMVIQIRXJSVWYGGIWWJYPGETXYVMRKMWEVSFYWXLMKLEJJMRMX] MRXIVEGXMSRFIX[IIRXLIGETXYVMRKQSPIGYPIERHXLIPMKERH 1SRSGPSREPERXMFSHMIWEVIJVIUYIRXP]YWIHEWGETXYVMRKEKIRXW)ZIRMJ XLIEJJMRMX]MWLMKLXLIVI[MPPSJXIRFIEGIVXEMREQSYRXSJHMWWSGMEXMSR SJXLIPMKERHJVSQXLIWYVJEGIHYVMRKXLIGSYVWISJEREREP]WMW7MRGI PMKERHMWVIJVIWLIHJSVIEGLG]GPIXLMWGERKIRIVEPP]FIMKRSVIHMR GSRGIRXVEXMSREWWE]W 8LIGETXYVMRKQSPIGYPIMWEXXEGLIHXSXLIWYVJEGIYWMRKSRISJXLI GSZEPIRXGLIQMGEPETTVSEGLIWHIWGVMFIHMRXLITVIZMSYWWIGXMSRW Immobilizing small molecules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
SURFACE PLASMON RESONANCE-BASED SYSTEMS
SURFACE PLASMON RESONANCE-BASED SYSTEMS ADVANCED METHODS IN BIOENGINEERING LABORATORY 3/1/2011 1 Schedule Week 1: Introduction Reagents preparation Ligand immobilization of Protocol 1 Week 2: Kinetics
More informationValidation of a concentration assay using Biacore C
GE Healthcare Application Note 48 Biacore systems Validation of a concentration assay using Biacore C Guideline for development of a GxP - compliant concentration assay Support for informed decision-making
More informationGE Healthcare Life Sciences. Biacore Assay Handbook
GE Healthcare Life Sciences Biacore Assay Handbook 1 Introduction 1.1 What Biacore systems measure... 5 1.2 Where Biacore systems are used... 5 1.3 Scope of this book... 6 1.4 Biacore system range...
More informationLabel-free interaction analysis in realtime using surface plasmon resonance
GE Healthcare Technology Note 23 Biacore systems Label-free interaction analysis in realtime using surface plasmon resonance Providing quantitative data on: report point Specificity sensorgram To what
More informationGE Biacore T Check that the waste bottle is empty.
GE Biacore T200 General Care and Maintenance The instrument should be left ON at all times, and in Standby Mode. Report problems immediately in the booking system: https://ppms.us/hms-cmi. Refer to the
More informationThe World Leader in SPR Technology. Jimmy Page, PhD, Biacore, Inc.
The World Leader in SPR Technology Jimmy Page, PhD, Biacore, Inc. Objectives of Biacore Experiments Yes/No Data» Is there binding?» Ligand Fishing Concentration Analysis: How MUCH? Active Concentration
More informationApplication of Biacore Technology
Principles and typical results Application of Biacore Technology Common types of Biacore analyses Specificity analysis Is my molecule of interest specific for its target? Multiple binding analysis In which
More informationLabel-Enhanced SPR Improves the Detectability of Label-Free Surface Plasmon Resonance Analysis 100x
episentec Label-Enhanced SPR Improves the Detectability of Label-Free Surface Plasmon Resonance Analysis 1x Anders Hanning, Episentec Drug Discovery 15, Telford, 2-3 September 215 Episentec - Better Biosensors
More informationprotein interaction analysis tech note 5367
protein interaction analysis tech note 5367 Rapid Optimization of Immobilization and Binding Conditions for Kinetic Analysis of Protein-Protein Interactions Using the ProteOn XPR36 Protein Interaction
More informationImproving biosensor analysis
JOURNAL OF MOLECULAR RECOGNITION J. Mol. Recognit. 1999;12:279 284 Improving biosensor analysis David G. Myszka* Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84132, USA The quality
More informationSolvent Correction versus In-line Reference Measurement
Technical Note Solvent Correction versus In-line Reference Measurement Optical systems such as SPR and BLI often have difficulty with nonspecific noise when measuring low molecular weight analyte in organic
More informationSurface plasmon resonance
Surface plasmon resonance P. Anton van der Merwe 1. INTRODUCTION 3 2. PRINCIPLES AND APPLICATIONS OF SURFACE PLASMON RESONANCE. 4 2.1. Principles 4 2.2. Applications 5 2.2.1. What SPR is good for 5 2.2.2.
More informationReducing Non-Specific Binding in Surface Plasmon Resonance Experiments
1 Reducing Non-Specific Binding in Surface Plasmon Resonance Experiments SUMMARY Reducing non-specific binding (NSB) is essential to generating accurate data with SPR The effect of bovine serum albumin,
More informationReal-Time Biomolecule Interaction Analysis Biacore
Real-Time Biomolecule Interaction Analysis Biacore 李宗樹 Forest.LEE@ge.com GE Healthcare Life Sciences Content Introduce to Interaction SPR, ITC, DSC Kinetics and Affinity Introduce to Biacore Applications
More informationprotein interaction analysis
protein interaction analysis protocol guide 5821 Guide to Ligand Immobilization on the ProteOn XPR36 System Laura Moriarty, Bio-Rad Laboratories, Inc., 2000 Alfred Nobel Drive, Hercules, CA 94547 USA.
More informationDirect genotyping of C3435T single nucleotide polymorphism in unamplified human MDR1 gene using a surface plasmon resonance imaging DNA sensor
Analytical and Bioanalytical Chemistry Electronic Supplementary Material Direct genotyping of C3435T single nucleotide polymorphism in unamplified human MDR1 gene using a surface plasmon resonance imaging
More informationTowards an optimized in-vitro SPR assay for antibody Fcg receptor binding kinetics
Towards an optimized in-vitro SPR assay for antibody Fcg receptor binding kinetics Åsa Frostell 1, Robert Karlsson 1, Jerrard Hayes 2, Matilda Lindgren 1, Pauline Rudd 2, and Cecilia Annerén 1 1 GE Healthcare
More informationProtein Interaction Analysis
/proteininteraction/ ProteOn XPR36 Protein Interaction Array System 310 Instrument 310 Software 312 Regulatory Tools 314 Sensor Chips 315 Kits, Reagents, and Consumables 317 Protein Interaction Analysis
More informationThe use of surface plasmon resonance to guide the choice of nucleic acid oligomers for co-crystallisation with proteins
The use of surface plasmon resonance to guide the choice of nucleic acid oligomers for co-crystallisation with proteins Clare Stevenson John Innes Centre, Norwich, U.K. clare.stevenson@jic.ac.uk RAMC,
More informationBiacore System description. GE Healthcare. Biacore label-free interaction analysis. Optional software packages
GE Healthcare Biacore label-free interaction analysis Biacore 4000 Biacore 4000 offers a complete solution for large-scale, label-free molecular interaction analysis, delivering high throughput without
More informationSensitive protein:ligand biochemical assays using Corning Epic label-free technology on the EnSpire Multimode Plate Reader
APPLICATION NOTE Label-free Technology Authors Heidi Morgan, M.S. Sarah Burroughs, Ph.D. Paul Butler Janet Park-Bewsher, MBA Tim Cloutier, Ph.D. PerkinElmer, Inc. Waltham, MA 241 USA Sensitive protein:ligand
More informationLigand Binding Assay strategies to support early drug development. Sarah Childs, Tina Panchal, Rose Edwards GlaxoSmithkline
Ligand Binding Assay strategies to support early drug development Sarah Childs, Tina Panchal, Rose Edwards GlaxoSmithkline Overview PK Study Design Bioanalytical Strategy Method Development Validation
More informationHow to run Alpha assay: How to setup an Alpha assay Make your own assay!
How to run Alpha assay: How to setup an Alpha assay Make your own assay! 1 2009 PerkinElmer AlphaLISA kits - recommendations before starting the assay Samples: Phenol red and hemoglobin: choose AlphaLISA
More informationCharacterization of Aptamer Binding using SensíQ SPR Platforms
Characterization of Aptamer Binding using SensíQ SPR Platforms APPLICATION NOTE INTRODUCTION Aptamers have the potential to provide a better solution in diagnostics and other research areas than traditional
More informationBiacore The high performance research system. Work with high sensitivity
Biacore 3000 The high performance research system Work with high sensitivity direct detection of small molecules at < 1 nm concentration increased resolution for kinetic analysis measurement of weak affinities
More informationM-Beads Magnetic Silica Beads Tools
M-Beads Magnetic Silica Beads Tools MoBiTec GmbH 2010 Page 2 Contents Technical Data... 3 Application... 4 General Information... 4 Bead Usage... 4 Additional Materials Needed... 4 Protocols... 5 Protein
More informationBinding Analysis of a Novel Peptide to Malaria Knob Protein
Binding Analysis of a Novel Peptide to Malaria Knob Protein http://www.nuigalway.ie/cryst/ oscail_tutorial/moilin/ biomolecules/ala_gly.png Jessica Preston Professors C. Takoudis, A. Chisti, and G. Jursich
More informationSupporting Information
Copyright WILEY-VCH Verlag GmbH & Co. KGaA, 69469 Weinheim, Germany, 2014. Supporting Information for Small, DOI: 10.1002/smll.201303558 Ultraspecific and Highly Sensitive Nucleic Acid Detection by Integrating
More informationPI3 Kinase Assay Kit. Catalog Number KA assays Version: 05. Intended for research use only.
PI3 Kinase Assay Kit Catalog Number KA0904 400 assays Version: 05 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Background... 3 General Information... 4 Materials Supplied...
More informationDesign and Validation of a Non Cell-based Receptor Binding Assay for the Detection of Neutralizing Antibodies to a Biological Therapeutic
Design and Validation of a Non Cell-based Receptor Binding Assay for the Detection of Neutralizing Antibodies to a Biological Therapeutic Shalini Gupta Associate Director Amgen, Thousand Oaks, CA shalinig@amgen.com
More informationCharacterization of a human recombinant antibody fragment to be used in a diagnostic test
LABORATORY EXERCISE 1 Characterization of a human recombinant antibody fragment to be used in a diagnostic test Evaluation by SDS-PAGE, NanoDrop, ELISA, Biacore and Antibody microarray. Supervisors: Elin
More informationCyfra 21-1 IRMA. Product information Information about other products is available at: Userś Manual DE52100
Product information Information about other products is available at: www.demeditec.com Userś Manual Cyfra 21-1 IRMA The CYFRA 21.1 IRMA system provides a direct in vitro quantitative determination of
More informationFragment-based screening of enzyme drug targets: Microfluidic mobility shift assay improves confidence in candidate selection
Fragment-based screening of enzyme drug targets: Microfluidic mobility shift assay improves confidence in candidate selection Introduction Fragment-based lead discovery is establishing itself as valuable
More informationTAG-LITE RECEPTOR LIGAND BINDING ASSAY
TAG - L I T E TAG-LITE RECEPTOR LIGAND BINDING ASSAY PROTOCOL ASSAY PRINCIPLE The Tag-lite Ligand Binding Assay is a homogeneous alternative to radio ligand binding assays for HTS and compound profiling.
More informationAssays and Strategies for Immunogenicity Assessment. Steven J Swanson, Ph.D. Executive Director, Medical Sciences Clinical Immunology, Amgen
Assays and Strategies for Immunogenicity Assessment Steven J Swanson, Ph.D. Executive Director, Medical Sciences Clinical Immunology, Amgen General Antibody Assay Strategy Correlation of clinical findings
More informationAppNote 5/2006 ABSTRACT
AppNote 5/26 Stir Bar Sorptive Extraction Based on Restricted Access Material for the Direct Extraction of Drugs and Metabolites in Biological Fluids Wayne M. Mullett and Elizabeth Kwong Merck Frosst,
More informationComparison of LANCE Ultra TR-FRET to PerkinElmer s Classical LANCE TR-FRET Platform for Kinase Applications
Comparison of LANCE Ultra TR-FRET to PerkinElmer s Classical LANCE TR-FRET Platform for Kinase Applications LANCE ULTRA TR-FRET TECHNOLOGY A P P L I C A T I O N N O T E Introduction Protein kinases play
More informationMasayoshi Honda, Jeehae Park, Robert A. Pugh, Taekjip Ha, and Maria Spies
Molecular Cell, Volume 35 Supplemental Data Single-Molecule Analysis Reveals Differential Effect of ssdna-binding Proteins on DNA Translocation by XPD Helicase Masayoshi Honda, Jeehae Park, Robert A. Pugh,
More informationShuo Wang, Manoj Munde, Siming Wang, W. David Wilson
Background: Yoshihiro Miura Minor Groove to Major Groove, an Unusual DNA Sequence-Dependent Change in Bend Directionality by a Distamycin Dimer Shuo Wang, Manoj Munde, Siming Wang, W. David Wilson Drugs
More informationCytokine 51 (2010) Contents lists available at ScienceDirect. Cytokine. journal homepage:
Cytokine 51 (2010) 107 111 Contents lists available at ScienceDirect Cytokine journal homepage: www.elsevier.com/locate/issn/10434666 Quantification of Interleukin-6 in cell culture medium using surface
More informationApplication Note. Kwasi Antwi, Amanda Ribar, Urban A. Kiernan, and Eric E. Niederkofler Thermo Fisher Scientific, Tempe, Arizona
Analysis of an Antibody Drug Conjugate using MSIA D.A.R.T. S. Technology, an Integral Part of Ligand Binding Mass Spectrometric Immunoassay (LB-MSIA) Workflow Application Note Kwasi Antwi, Amanda Ribar,
More informationPlease note that in order to obtain useful results, the input values should be in the correct units (as indicated per input cell).
1. Calculations This document contains a number of formulas used with surface plasmon resonance and biomolecular interaction analysis. For the convenience of the reader, an Excel spreadsheet (.xlsm) is
More informationBiacore 8K. One solution for small molecule and biotherapeutic screening/characterization. GE Healthcare. Label-free interaction analysis
GE Healthcare Label-free interaction analysis Biacore 8K Biacore 8K efficiently delivers binding data with the quality you expect, meeting your toughest challenges in small molecule and biotherapeutic
More informationTag-lite Tachykinin NK1 labeled Cells, ready-to-use (transformed & labeled), 200 tests* (Part# C1TT1NK1)
TAG - L I T E Tag-lite Tachykinin NK1 Receptor Ligand Binding Assay protocol Tachykinin NK1 labeled cells for: 200 tests Part#: C1TT1NK1 Lot#: 03-1 March 2016 (See expiration date on package label) Store
More informationEPIGENTEK. EpiQuik Histone Demethylase LSD1 Activity/Inhibition Assay Kit. Base Catalog # P-3076 PLEASE READ THIS ENTIRE USER GUIDE BEFORE USE
EpiQuik Histone Demethylase LSD1 Activity/Inhibition Assay Kit Base Catalog # PLEASE READ THIS ENTIRE USER GUIDE BEFORE USE The EpiQuik Histone Demethylase LSD1 Activity/Inhibition Assay Kit is very suitable
More informationThermo Scientific Mass Spectrometric Immunoassay (MSIA) Pipette Tips. Next generation immunoaffinity. Robust quantitative platform
Thermo Scientific Mass Spectrometric Immunoassay (MSIA) Pipette Tips Next generation immunoaffinity Robust quantitative platform Immunoaffinity sample preparation Thermo Scientific Mass Spectrometric Immunoassay
More informationMSD Immuno-Dot-Blot Assays. A division of Meso Scale Diagnostics, LLC.
MSD Immuno-Dot-Blot Assays Example: High Throughput Western Blots Replacements Traditional Western Blots High content Molecular weight and immunoreactivity Labor and protein intensive Inherently low throughput
More informationvalidation report for TaqMan Roundup Ready Quantification Kit
validation report for TaqMan Roundup Ready Quantification Kit Life Technologies offers a breadth of products DNA RNA protein cell culture instruments For Research Use Only. Not intended for any animal
More informationCHO Host Cell Proteins 3 rd Generation
CHO Host Cell Proteins 3 rd Generation Immunoenzymetric Assay for the Measurement of CHO Host Cell Proteins Catalog # F550 Intended Use This kit is intended for use in determining the presence of host
More informationRayBio Human bfgf ELISA Kit
RayBio Human bfgf ELISA Kit User Manual (for Cell Lysate and Tissue Lysate) (Revised Mar 1, 2012) RayBio Human bfgf ELISA Kit Protocol (Cat#: ELH-bFGF-001C) RayBiotech, Inc. We Provide You With Excellent
More informationCase Studies ZoBio
Case Studies 2011 ZoBio ZoBio Corporate Overview Founded as Dutch BV 11/2004 Full access to all lab facilities of UL Self funded (grants and commercial activities) Doubled income 5 consecutive years 9
More informationA2LA. R231 Specific Requirements: Threat Agent Testing Laboratory Accreditation Program. December 6, 2017
Laboratory Page 1 of 17 Laboratory December 6, 2017 2017 by A2LA All rights reserved. No part of this document may be reproduced in any form or by any means without the prior written permission of A2LA.
More informationBiacore comparability tool for quantitating binding similarities in IgG Fcγ receptor analysis
GE Healthcare Biacore comparability tool for quantitating binding similarities in IgG Fcγ receptor analysis Assessment and control of Fc functionality during biotherapeutic antibody development and manufacturing
More informationHuman Cytokine Assays: Tissue Culture Kit (96-well)
Human Cytokine Assays: Tissue Culture Kit (96-well) 17059-v8-2017Oct 1 MSD T-PLEX Cytokine Assays Human Cytokine Assays: Tissue Culture Kit (96-well) This package insert must be read in its entirety before
More informationPerformance of the Sievers 500 RL On-Line TOC Analyzer
GE Water & Process Technologies Analytical Instruments Performance of the Sievers 500 RL On-Line TOC Analyzer imagination at work Page 2 of 10 Introduction To determine the performance characteristics
More informationPER.C6 cells Host Cell Proteins
PER.C6 cells Host Cell Proteins Immunoenzymetric Assay for the Measurement of PER.C6 cell line Host Cell Proteins Catalog # F530 Intended Use This kit is intended for use in determining the presence of
More informationBio-Plex suspension array system
Multiplex Assays Bio-Plex suspension array system tech note 64 Profiling of Human, Canine, and Rat Urine Samples Using Bio-Plex Pro RBM Kidney Toxicity Assays L. Stephen, H. Schnaars, K. Marshall, H. Akey,
More informationConverting your ELISA from horseradish peroxidase to alkaline phosphatase using NovaBright chemiluminescence detection reagents
Application note DynaLight Substrate with RapidGlow Enhancer Converting your ELISA from horseradish peroxidase to alkaline phosphatase using NovaBright chemiluminescence detection reagents Introduction
More informationDeveloping a natural partnership for rapid, sensitive identification of binding partners
GE Healthcare Technology Note 24 Biacore systems Developing a natural partnership for rapid, sensitive identification of binding partners Biacore 3000 and mass spectrometry Summary The coupling of label-free
More informationMicroarray Industry Products
Via Nicaragua, 12-14 00040 Pomezia (Roma) Phone: +39 06 91601628 Fax: +39 06 91612477 info@lifelinelab.com www.lifelinelab.com Microarray Industry Products Page 10 NBT / BCPIP Chromogenic phosphatase
More informationHuman Serum Albumin Assay
Human Serum Albumin Assay Immunoenzymetric Assay for the Measurement of Human Serum Albumin Catalog # F055 Intended Use This kit is intended for use in quantitating human albumin (HSA). The kit is for
More informationMSD GOLD Streptavidin and Avidin Plates
MSD GOLD Streptavidin and Avidin Plates SECTOR Plates QUICKPLEX Plates 96-well Streptavidin L15SA L55SA 96-well Small Spot Streptavidin L45SA N/A 96-well High Bind Avidin L15AB L55AB FOR RESEARCH USE ONLY.
More informationMagSi Beads. Magnetic Silica Beads for Life Science and Biotechnology study
MagSi Beads Magnetic Silica Beads for Life Science and Biotechnology study MagnaMedics Diagnostics B.V. / Rev. 9.2 / 2012 Wide range of products for numerous applications MagnaMedics separation solutions
More informationLigand Binding Assays: Summary and Consensus from the Bioanalytical Workshop (CC V)
Ligand Binding Assays: Summary and Consensus from the Bioanalytical Workshop (CC V) Binodh DeSilva Executive Director Immunochemistry and Biomarker Development Bristol-Myers Squibb Contributors Lauren
More informationBoTest A/E Botulinum Neurotoxin Detection Kit- Detailed Description
Figure 1. BoTest A/E Reporter. (A) BioSentinel s BoTest A/E Reporter. CFP and YFP are connected by SNAP-25 (amino acids 141-206). The cleavage sites for each BoNT sero-type are indicated. (B) A FRET assay
More informationA handheld system for DNA test based on Lab on chip technologies. Marco Bianchessi
A handheld system for DNA test based on Lab on chip technologies Marco Bianchessi History 2 Mid 90s: Lab on chip introduction From niche to high-volumes products What is needed: 3 Miniaturization 75 000
More informationGSI Equine IL-10 ELISA Kit- Cell Lysate DataSheet
IL-10, also known as human cytokine synthesis inhibitory factor (CSIF), is an antiinflammatory cytokine that is produced by T cells, NK cells, mast cells and macrophages (1,2,3). It is capable of inhibiting
More informationFusion Analytical Method Validation
Fusion QbD Software System Fusion Analytical Method Validation The Only Software That Has It All! 100% aligned with FDA/ICH Quality by Design (QbD) guidances! Can be used for LC and Non-LC methods (e.g.
More informationUniversal Kinase Assay Kit (Fluorometric) For monitoring ADP formation, which is directly proportional to enzyme phosphotransferase activity
ab138879 Universal Kinase Assay Kit (Fluorometric) Instructions for Use For monitoring ADP formation, which is directly proportional to enzyme phosphotransferase activity This product is for research use
More informationProtocol. NEXTERION Slide H. Protein application
Seite: 1/8 1 Introduction... 2 2 Storage and handling... 3 3 General precautions... 3 4 Reagents required... 4 5 Equipment required... 4 6 Protein concentration for spotting... 5 7 Array printing... 5
More informationSodium Cyanoborohydride
528PR 01 G-Biosciences 1-800-628-7730 1-314-991-6034 technical@gbiosciences.com A Geno Technology, Inc. (USA) brand name Sodium Cyanoborohydride A Reducing Agent for Stable Bonds Between Aldehyde and Amine
More informationData Sheet. PD-1[Biotinylated]:PD-L2 Inhibitor Screening Assay Kit Catalog # Size: 96 reactions
Data Sheet PD-1[Biotinylated]:PD-L2 Inhibitor Screening Assay Kit Catalog # Size: 96 reactions DESCRIPTION: Cell signaling through the PD-1 receptor upon binding the PD-L2 ligand attenuates immune responses
More informationVerification of Compendial Methods
Verification of Compendial Methods ภญ.ดร ดร.ส ภาณ ดวงธ รปร ชา ส าน กยาและว ตถ เสพต ด กรมว ทยาศาสตร การแพทย 7 ม ถ นายน 2556 1 Scopes : Overview Asean Analytical Validation Guidelines Verification of Compendial
More informationHuman IL10RB ELISA Pair Set ( CRFB4 )
Human IL10RB ELISA Pair Set ( CRFB4 ) Catalog Number : SEK10945 To achieve the best assay results, this manual must be read carefully before using this product and the assay is run as summarized in the
More informationGlobal Headquarters 86 Cummings Park Woburn, MA Tel:
Human beta-defensin 2 ELISA Kit Cat:RK00193 This ELISA kit used for quantitation of human Beta Defensin-2 (BD-2) concentration in cell culture supernate, serum and plasma. For research use only, and it
More informationMSD 96-Well MULTI-ARRAY and MULTI-SPOT Human Cytokine Assays: Base Kit
MSD 96-Well MULTI-ARRAY and MULTI-SPOT Human Cytokine Assays: Base Kit Summary MSD Cytokine Assays measure one to ten cytokines in a 96-well MULTI-ARRAY or MULTI-SPOT plate. The assays employ a sandwich
More informationVALIDATION GUIDE FOR CHROMOGENIC ASSAY FOR ACTIZYME Anti-FIIa
VALIDATION GUIDE FOR CHROMOGENIC ASSAY FOR ACTIZYME Anti-FIIa Chromogenic assay for testing heparins (UFH, LMWH and Enoxaparin) in purified systems by measurement of FIIa Inhibition, in compliance with
More informationGlobal Headquarters 86 Cummings Park Woburn, MA Tel:
Human beta-defensin 1 ELISA Kit Cat:RK00211 This ELISA kit used for quantitation of human Defensin Beta 1 (BD-1) concentration in cell culture supernate, serum and plasma. For research use only, and it
More informationHuman Erythropoietin (EPO) kit
TECHNICAL DATA SHEET AlphaLISA Research Reagents Caution: For Laboratory Use. A research chemical for research purposes only. Human Erythropoietin (EPO) kit Product No.: AL206 C/F Lot specific kit information
More informationMSD 96-Well MULTI-ARRAY and MULTI-SPOT Mouse Cytokine Assays: Tissue Culture Kit
MSD 96-Well MULTI-ARRAY and MULTI-SPOT Mouse Cytokine Assays: Tissue Culture Kit Summary MSD Cytokine Assays measure one to ten cytokines in a 96-well MULTI-ARRAY or MULTI-SPOT plate. The assays employ
More informationHuman Interleukin 6 (IL6) Kit
TECHNICAL DATA SHEET AlphaLISA Research Reagents Caution: For Laboratory Use. A research chemical for research purposes only. Human Interleukin 6 (IL6) Kit Product No.: AL223 C/F Lot specific kit information
More informationData Sheet. PD-1:PD-L1[Biotinylated] Inhibitor Screening Assay Kit Catalog # Size: 96 reactions
Data Sheet PD-1:PD-L1[Biotinylated] Inhibitor Screening Assay Kit Catalog # 72003 Size: 96 reactions DESCRIPTION: Cell signaling through the PD-1 receptor upon binding the PD-L1 ligand attenuates immune
More informationHOOK Sulfo-NHS-Biotin
126PR-03 G-Biosciences 1-800-628-7730 1-314-991-6034 technical@gbiosciences.com A Geno Technology, Inc. (USA) brand name HOOK Sulfo-NHS-Biotin For the coupling of biotin to protein amine groups (Cat. #
More informationExplore the future. Automotive Test Systems Process & Environmental Medical Semiconductor Scientific
Explore the future Automotive Test Systems Process & Environmental Medical Semiconductor Scientific Label-free Bio-Affinity Analysis Surface Plasmon Resonance (SPR) is an established tool in the life science
More informationMembrane Protein Arrays: Application for GPCR Screening
Membrane Protein Arrays: Application for GPCR Screening Ye Fang, Anthony G. Frutos, Brian L. Webb, Yulong Hong, Fang Lai, Laurent Picard and Joydeep Lahiri. Corning Incorporated, Corning, NY, USA PicardL@corning.com
More informationHuman IgG Antigen ELISA Kit
Human IgG Antigen ELISA Kit Catalog No: IHUIGGKT Lot No: SAMPLE INTENDED USE This human immunoglobulin G antigen assay is intended for the quantitative determination of total human IgG antigen in serum,
More informationComplementary use of Label-Free Real-Time Biosensors in Drug Discovery of Monoclonal Antibodies
Complementary use of Label-Free Real-Time Biosensors in Drug Discovery of Monoclonal Antibodies 5 Yasmina Noubia Abdiche Pfizer, Inc United States of America 1. Introduction Biosensors measure the real-time
More informationMouse ICAM-1 / CD54 ELISA Pair Set
Mouse ICAM-1 / CD54 ELISA Pair Set Catalog Number : SEK50440 To achieve the best assay results, this manual must be read carefully before using this product and the assay is run as summarized in the General
More informationdoi: /s (03) J. Mol. Biol. (2003) 328,
doi:10.1016/s0022-2836(03)00360-7 J. Mol. Biol. (2003) 328, 1173 1183 Transforming Growth Factor-beta (TGF-b) Binding to the Extracellular Domain of the Type II TGF-b Receptor: Receptor Capture on a Biosensor
More informationUser Manual. NGS Library qpcr Quantification Kit (Illumina compatible)
NGS Library qpcr Quantification Kit (Illumina compatible) User Manual 384 Oyster Point Blvd, Suite 15 South San Francisco, CA 94080 Phone: 1 (888) MCLAB-88 Fax: 1 (650) 872-0253 www.mclab.com Contents
More informationHighly Sensitive Surface Plasmon Resonance Sensor on Nanoscale Bioactive Surfaces for Specific Detection of Tri-Nitro Toluene
Mater. Res. Soc. Symp. Proc. Vol. 951 2007 Materials Research Society 0951-E07-12 Highly Sensitive Surface Plasmon Resonance Sensor on Nanoscale Bioactive Surfaces for Specific Detection of Tri-Nitro Toluene
More informationApplication Note. Authors. Abstract
Automated, High Precision Tryptic Digestion and SISCAPA-MS Quantification of Human Plasma Proteins Using the Agilent Bravo Automated Liquid Handling Platform Application Note Authors Morteza Razavi, N.
More informationFast and easy multiplex immunoassay development Cytokines as an example
TECHNICAL NOTES Fast and easy multiplex immunoassay development Cytokines as an example Summary Fast and easy porting of existing singleplex immunoassays in the development of high performance multiplex
More informationInline Conditioning system
GE Healthcare Frequently asked questions Inline Conditioning system Buffer preparation can be both time-and spaceconsuming and can easily become a challenge in biomanufacturing. In-line preparation of
More informationprotein interactions tech
protein interactions tech note 6254 The Proten HTE Sensor Chip: ovel Surface for Stable Capture of Histidine-Tagged Proteins for Protein Small Molecule Interaction Analysis Vered Bronner 1, Moran Edri
More informationNanophotonics: principle and application. Khai Q. Le Lecture 11 Optical biosensors
Nanophotonics: principle and application Khai Q. Le Lecture 11 Optical biosensors Outline Biosensors: Introduction Optical Biosensors Label-Free Biosensor: Ringresonator Theory Measurements: Bulk sensing
More information